XOMA Royalty acquires 50% of Twist Bioscience's royalty/milestone economics for $15M

XOMA Royalty Corp

Acquired 50% economic interest in milestones/royalties from Twist's 60+ early-stage programs across 30 partners for $15M upfront.
XOMA's portfolio now exceeds 100 assets, spanning commercial to pre-clinical programs.
Twist's Biopharma Solutions business unit yields future payments under biopharma services agreements.
Chief Investment Officer Brad Sitko cites potential for superior risk-adjusted returns.
Gibson, Dunn & Crutcher served as XOMA's legal advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.